IN THIS ARTICLE

Citations

1. Gershon AA (2009). Varicella zoster virus. In RD Feigin et al., eds., Feigin and Cherry's Textbook of Pediatric Infectious Diseases, 6th ed., vol. 2, pp. 2077–2088. Philadelphia: Saunders Elsevier.

2. Chen N, et al. (2010). Corticosteroids for preventing postherpetic neuralgia (Review). Cochrane Database of Systematic Reviews (12).

3. Dubinsky RM, et al. (2004, reaffirmed 2008). Practice parameter: Treatment of postherpetic neuralgia. An evidence-based report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology, 63(6): 959–965.

Other Works Consulted

• Centers for Disease Control and Prevention (2008). Prevention of herpes zoster: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR, 57(05): 1–30. Also available online: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5705a1.htm. [Erratum in MMWR, 57(28): 779. Also available online: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5728a5.htm.]

• Gilden DH (2008). Acute viral central nervous system diseases. In DC Dale, DD Federman, eds., ACP Medicine, section 11, chap. 16. Hamilton, ON: BC Decker.

• Habif TP (2010). Herpes zoster. In Clinical Dermatology, A Color Guide to Diagnosis and Therapy, 5th ed., pp. 479–490. Philadelphia: Mosby.

• Herpes zoster vaccine (Zostavax) revisited (2009). Medical Letter on Drugs and Therapeutics, 52(1339): 41.

• Strangfeld A, et al. (2009). Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-a agents. JAMA, 301(7): 727–744.

• Wolff K, Johnson RA (2009). Varicella-zoster virus infections. In Fitzpatrick's Color Atlas and Synopsis of Clinical Dermatology, 6th ed., pp. 837–845. New York: McGraw-Hill Medical.